News

Deal expands pharma giant’s influence in inflammation and immunology markets

Includes 20 million more doses by the end of the 2021

The $17.4-billion deal, CDMO says, will help expand its offerings in the clinical development space

Via investment partnership with Taishin Holdings, will begin offering manufacturing services in C&GT space

Survey draws attention to the need for improving issues surrounding supply chain visibility

Biden touts provisions administration believes can curb spending on pharmaceuticals

Site is located in the state of Gujarat, a major hub for pharma logistics

Collaboration focuses on continuing to improve time to therapy and medication adherence for patients, while effectively optimizing clinical data

Upon deal completion, group will acquire company’s oncology product portfolio for $846 million

Latest report indicates that air cargo demand is outperforming pre-Covid stats from 2019

Financial commitment is predicted to more than double the biopharma site’s manufacturing capabilities

Transaction expands CDMO’s services, including more solutions surrounding commercial manufacturing

Five-year deal covers manufacturing of molecules, ranging from monoclonal antibodies to antibody-drug conjugates

Subject to regulatory approval, CDMO will produce mRNA vaccine on a commercial scale

The latest people news happenings over the past month

The biggest areas of adjustment in patient support brought on by changes in consumer and physician behavior

The Discovery Centre will be powered by AI technology, robotics, among other features

Transaction is anticipated to further Novo’s research in the field of RNAi therapeutics

Acquisition of biopharma company features sotatercept, which is in Phase III trials for the treatment of pulmonary arterial hypertension

Financial commitment expected to increase plant's process development and manufacturing capacity

Approval is for the 50-µg dosage

Opens a ‘Cold Chain Packaging Center of Excellence’ in Kentucky, while expanding services globally

ConvergeHEALTH Safety intended to automate pharmacovigilance case processing

Separation process expected to be completed in 18-24 months

White House announces official endorsement, paving way for Senate confirmation process

It’s not just innovator pharma companies concerned with the proposed compromise to Medicare price negotiations and inflation-based rebates

Expansion expected to more than double the plant’s footprint

PBM fees and vertical integration are also at the top of the list